

CANC

Tema Oncology ETF

Analyst Report

CANC is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations.

ESG Themes and Scores

5.98/10

ESG Rate

35.91%

Global Percentile

28.32%

Peer Percentile

Performance Data

	CANC	ETF Database Category Average	Factset Segment Average
1 Month	3.34%	4.51%	4.77%
3 Month	-6.77%	-0.36%	-1.63%
YTD Return	5.11%	6.63%	8.39%
1 Year Return	-1.97%	5.24%	-0.25%
3 Year Return	N/A	-0.15%	-5.28%
5 Year Return	N/A	2.01%	-1.16%

Top 5 Holdings

Symbol	Holding	% Assets
AZN	AstraZeneca PLC	5.77%
LLY	Eli Lilly and Company	4.67%
BBIO	BridgeBio Pharma, Inc.	4.49%
RVMD	Revolution Medicines, Inc.	4.28%
MRK	Merck & Co., Inc.	4.18%

Vitals

Issuer	Tema Global Ltd.
Brand	Tema
Structure	ETF
Expense Ratio	0.75%
Inception	Aug 15, 2023
Index Tracked	N/A

ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	Growth
Region (General)	Global
Region (Specific)	Broad

FactSet Classifications

Segment	Equity: Global Pharma, Biotech & Life Sciences
Category	Sector
Focus	Health Care
Niche	Pharma, Biotech & Life Sciences
Strategy	Active
Weighting	Proprietary

